Drugmakers Seek More Detail in FDA Guidance on Increased Diversity in Clinical Trials

Drug Industry Daily
A A
Drugmakers were generally supportive but raised some questions and concerns in comments on the FDA’s draft guidance on increasing diversity in clinical trials.

To View This Article:

Login

Subscribe To Drug Industry Daily